FasCure Therapeutics

FasCure Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for pulmonary arterial hypertension (PAH) and other conditions involving pathological cell proliferation. The company's lead candidate, FT-001, is a recombinant version of the human Fas ligand designed to trigger programmed cell death specifically in the overgrown vascular cells that obstruct blood flow in PAH patients. Unlike current treatments that primarily focus on vasodilation, FasCure's approach aims to reverse vascular remodeling and restore normal lung function. The company's core technology is based on research conducted at Vanderbilt University and targets the Fas/Fas-ligand signaling pathway. FasCure is currently advancing its lead program through IND-enabling studies to transition into clinical trials.